期刊
MODERN RHEUMATOLOGY
卷 22, 期 2, 页码 298-302出版社
TAYLOR & FRANCIS LTD
DOI: 10.1007/s10165-011-0497-5
关键词
Behcet's disease; IL-6; Tocilizumab
类别
资金
- National Institute of Biomedical Innovation
- Chugai Pharmaceutical Co., Ltd.
A 47-year-old female patient with Beh double dagger et's disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This treatment suppressed the patient's clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Beh double dagger et's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据